$85.00
Disclaimer: This is a research chemical only. It’s not a medication, and it’s not approved for human or animal use outside of authorized studies
| Sequence | human IGF‑1 LR3 (long‑R3 insulin‑like growth factor‑1) – extended IGF‑1 analog with Arg substitution and N‑terminal extension |
| Molecular Formula | C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉ |
| Molecular Weight | ~9118 Da |
| PubChem CID | not indexed for this CAS |
| CAS # | 946870‑92‑4 |
Insulin-like Growth Factor-1 Long Arg3 (IGF-1 LR3) is a recombinant analog of native IGF-1 engineered with an arginine substitution at position three and an extended N-terminal peptide sequence. These modifications confer resistance to binding proteins (IGFBPs), resulting in significantly prolonged half-life and enhanced systemic bioavailability compared to endogenous IGF-1.
In experimental models, IGF-1 LR3 is examined for its ability to activate the IGF-1 receptor and downstream PI3K/Akt and MAPK signaling cascades, processes critical to cellular proliferation, differentiation, and survival. Researchers utilize this compound to explore mechanisms underlying skeletal muscle hypertrophy, tissue regeneration, and protein synthesis, as well as its role in glucose uptake and metabolic regulation.
Because of its extended activity window, IGF-1 LR3 allows for sustained observation of receptor dynamics, endocrine cross-talk, and feedback responses, providing a valuable investigative tool in studies of metabolic disease, growth factor biology, and anabolic signaling.
| Vial size | 1MG, 100MCG |
|---|
Reviews
There are no reviews yet.